MGC Pharmaceuticals Limited Investor Presentation (9552U)

TIDMMXC

RNS Number : 9552U

MGC Pharmaceuticals Limited

09 April 2021

 
 09 April 2021      MGC Pharmaceuticals Ltd 
   ASX Code:      Investor Presentation Update 
      MXC 
   LSE Code: 
      MXC

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phyto-derived medicines, has released an updated version of its investor presentation.

The presentation can be found on the MGC Pharma website here .

--Ends--

Authorised for release by the Board, for further information please contact:

 
 MGC Pharmaceuticals Ltd         UK PR Advisors - Tavistock 
  Roby Zomer                      Charles Vivian 
  CEO & Managing Director         +44 207 920 3150 
  +61 8 6382 3390                 Charles.Vivian@tavistock.co.uk 
  info@mgcpharma.com.au           Tim Pearson 
                                  +44 7983118 502 
                                  Tim.Pearson@tavistock.co.uk 
 UK Broker - Turner Pope         Australian PR/IR Advisors - Media 
  Andy Thacker                    & Capital Partners 
  Andy.Thacker@TurnerPope.com     Rod Hinchcliffe (IR) +61 412 277 
  Zoe Alexander                   377 
  Zoe.Alexander@TurnerPope.com    Rod.Hinchcliffe@mcpartners.com.au 
  +44 20 3657 0050

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUKVVRABUSRRR

(END) Dow Jones Newswires

April 09, 2021 02:00 ET (06:00 GMT)

Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Oct 2024 to Nov 2024